Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters

Abstract A worldwide effort to counter the COVID-19 pandemic has resulted in hundreds of candidate vaccines moving through various stages research and development, including several phase 1, 2 3 clinical trials. relatively small number these have been evaluated SARS-CoV-2 disease models, fewer a severe model. Here, DNA targeting spike protein delivered by jet injection, nCoV-S(JET), elicited neutralizing antibodies hamsters was protective both wild-type transiently immunosuppressed hamster models. This study highlights vaccine, we developed great potential move next stage preclinical studies, it also demonstrates that transiently-immunosuppressed Syrian hamsters, which recapitulate prolonged disease, can be used for evaluation efficacy spike-based vaccines.